Mifomelatide

Mifomelatide
Clinical data
Other namesTCMCB07; TCMCB-07
Routes of
administration		Subcutaneous injection[1]
Drug classMelanocortin MC3 and MC4 receptor antagonist[1]
Identifiers
  • (3S,11S,14S,17S,20R,23S)-3-[[(2S)-2-acetamidohexanoyl]amino]-N-[(2R)-1-[(2R)-2-carbamoylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]-17-[3-(diaminomethylideneamino)propyl]-14-(1H-indol-3-ylmethyl)-20-(naphthalen-2-ylmethyl)-2,5,13,16,19,22-hexaoxo-1,6,12,15,18,21-hexazabicyclo[21.3.0]hexacosane-11-carboxamide
CAS Number
PubChem CID
UNII
Chemical and physical data
FormulaC63H87N15O11
Molar mass1230.483 g·mol−1
3D model (JSmol)
  • CCCC[C@@H](C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H]2CCCN2C1=O)CC3=CC4=CC=CC=C4C=C3)CCCN=C(N)N)CC5=CNC6=CC=CC=C65)C(=O)N[C@H](C(C)C)C(=O)N7CCC[C@@H]7C(=O)N)NC(=O)C
  • InChI=1S/C63H87N15O11/c1-5-6-19-44(70-37(4)79)55(82)75-49-34-52(80)67-27-12-11-21-45(57(84)76-53(36(2)3)62(89)77-29-14-23-50(77)54(64)81)71-59(86)48(33-41-35-69-43-20-10-9-18-42(41)43)73-56(83)46(22-13-28-68-63(65)66)72-58(85)47(74-60(87)51-24-15-30-78(51)61(49)88)32-38-25-26-39-16-7-8-17-40(39)31-38/h7-10,16-18,20,25-26,31,35-36,44-51,53,69H,5-6,11-15,19,21-24,27-30,32-34H2,1-4H3,(H2,64,81)(H,67,80)(H,70,79)(H,71,86)(H,72,85)(H,73,83)(H,74,87)(H,75,82)(H,76,84)(H4,65,66,68)/t44-,45-,46-,47+,48-,49-,50+,51-,53+/m0/s1
  • Key:MBDALAXLRYJVAO-AXWWBJHISA-N

Mifomelatide (INNTooltip International Nonproprietary Name; developmental code name TCMCB07) is a melanocortin MC3 and MC4 receptor antagonist which is under development for the treatment of cachexia.[1][2][3][4] It is a synthetic cyclic peptide and is taken by subcutaneous injection.[1][3] Mifomelatide crosses the blood–brain barrier.[3][4] The drug is being developed by Endevica Bio.[1][2] As of February 2025, it is in phase 2 clinical trials.[1][2]

See also

References

  1. ^ a b c d e f "TCMCB 07". AdisInsight. 27 December 2024. Retrieved 25 February 2025.
  2. ^ a b c "Delving into the Latest Updates on Mifomelatide with Synapse". Synapse. 23 January 2025. Retrieved 25 February 2025.
  3. ^ a b c Kadakia KC, Hamilton-Reeves JM, Baracos VE (June 2023). "Current Therapeutic Targets in Cancer Cachexia: A Pathophysiologic Approach". American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 43 (43): e389942. doi:10.1200/EDBK_389942. PMC 11019847. PMID 37290034.
  4. ^ a b Ouyang Z, Tao W, Yu S, Zou M (2023). "Advances in pharmacotherapies in cancer-related cachexia". Oncology and Translational Medicine. 9 (1): 15–21. doi:10.1007/s10330-022-0611-1. ISSN 2095-9621.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.